Teleflex Aandeel

Teleflex EBITDA

De EBITDA (Winst voor rente, belastingen, afschrijvingen en amortisaties) van Teleflex (TFX) per 6 aug 2026 bedraagt 255,80 Miljoen USD. In het voorgaande jaar bedroeg EBITDA (Winst voor rente, belastingen, afschrijvingen en amortisaties) 159,02 Miljoen USD — een verandering van 60,86% (hoger).

EBITDA

255,80 MiljoenUSD

YoY

60,86%

Laatst bijgewerkt:

EBITDA (Winst voor rente, belastingen, afschrijvingen en amortisaties) van Teleflex is 2026 255,80 Miljoen USD. EBITDA (Winst voor rente, belastingen, afschrijvingen en amortisaties) van Teleflex was 2025 159,02 Miljoen USD. Het is daarmee 60,86% hoger lager dan het jaar ervoor.
Access this data via the Eulerpool API

Teleflex Aandelenanalyse

Wat doet Teleflex? Teleflex Inc. is a global company founded in 1943. The company is headquartered in Wayne, Pennsylvania, USA and operates in over 40 countries worldwide. It is a leading provider of medical devices, instruments, and accessories for various applications in clinical practice and patient care. The business model of Teleflex is based on the manufacturing and marketing of medical devices and instruments, particularly in the areas of anesthesia, vascular access, interventional medicine, pulmonary and thoracic surgery, urological care, cardiovascular diagnostics, and surgery. The company works closely with medical professionals and clinicians to develop high-quality products that meet the needs of patients and doctors. Teleflex is divided into several business segments, including angiography/diagnostics, anesthesia, oncology, vascular intervention, pulmonology, surgery, and urology. Each of these segments offers a wide range of products and solutions specifically tailored to the needs of doctors and patients. In the angiography/diagnostics segment, Teleflex offers a variety of products that can be used for the diagnosis and treatment of cardiovascular diseases and other medical conditions. These include catheters, guide wires, and sheaths. The anesthesia segment of Teleflex includes products such as ventilation bags, endotracheal tubes, and nebulizer systems. These products are essential for the successful performance of anesthesia procedures and can help doctors save valuable time and resources. The oncology segment of Teleflex offers a wide range of products specifically designed for the treatment of cancer patients. These include catheter-based systems that can facilitate the administration of drugs and other therapies. With the vascular intervention segment, Teleflex offers a comprehensive range of products and solutions specifically designed for the treatment of vascular diseases. These include balloon catheters, stents, and sheaths. The pulmonology segment of Teleflex offers products aimed at facilitating breathing and improving the quality of life for patients with chronic respiratory diseases. These include oxygen concentrators, tracheal tubes, and ventilators. The surgical segment of Teleflex offers a variety of solutions for performing surgical procedures, including surgical instruments, sutures, and wound care materials. The urology segment of Teleflex offers a wide range of products specifically designed for use in urology. These include catheters, wires, and stents. Teleflex is a leading company in the medical technology industry that specializes in the development and marketing of products that improve patients' quality of life and facilitate the work of doctors. With its innovative solutions and a focus on providing the best possible customer service and patient safety, Teleflex has taken on a significant role in the industry and will continue to be an important provider in this market in the future. Teleflex is een van de meest populaire bedrijven op Eulerpool.

Veelgestelde vragen over het aandeel Teleflex

EBITDA (Winst voor rente, belastingen, afschrijvingen en amortisaties) van Teleflex bedraagt 255,80 Miljoen USD in 2026.

EBITDA (Winst voor rente, belastingen, afschrijvingen en amortisaties) van Teleflex is veranderd van 159,02 Miljoen USD naar 255,80 Miljoen USD, wat een verandering van 60,86% vertegenwoordigt. De waarde is hoger dan het vorige jaar.

Op Eulerpool vindt u de volledige historische ontwikkeling van EBITDA (Winst voor rente, belastingen, afschrijvingen en amortisaties) Teleflex sinds 2006 – met jaarlijkse waarden, grafieken en gedetailleerde analyse.

EBITDA meet de operationele prestaties vóór de impact van de financiële structuur, de belastingomgeving en niet-kasmatige afschrijvingskosten.

EBITDA = EBIT + Afschrijvingen en amortisaties

USD van EBITDA (Winst voor rente, belastingen, afschrijvingen en amortisaties) is een belangrijke factor voor beleggers. Veranderingen in deze maatstaf kunnen sterke signalen geven voor toekomstige koersontwikkelingen.

Access this data via the Eulerpool API

Winst-en-verliesrekening — Teleflex

Alle kengetallen — Teleflex